# Talabostat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/talabostat

> The FDA approved talabostat, sponsored by BioXcel Therapeutics, Inc. (BTAIQ), on April 6, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is talabostat FDA approved?

Yes. The FDA approved talabostat, sponsored by BioXcel Therapeutics, Inc. (BTAIQ), on April 6, 2022. SEC Form 10-Q: "On April 6, 2022, we announced that the FDA approved IGALMITM sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." [Calendar and source filings](https://sec-api.dev/pdufa/talabostat)

Source: SEC Form 10-Q, accession 0001558370-24-015629, https://www.sec.gov/Archives/edgar/data/1720893/000155837024015629/btai-20240930x10q.htm (retrieved 2026-11-12). Last confirmed 2024-11-14. Cite: https://sec-api.dev/pdufa/talabostat#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | talabostat |
| Codes | BXCL701 |
| Sponsor | BioXcel Therapeutics, Inc. (BTAIQ) https://sec-api.dev/companies/btaiq/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### April 6, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001558370-24-015629): "On April 6, 2022, we announced that the FDA approved IGALMITM sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." https://www.sec.gov/Archives/edgar/data/1720893/000155837024015629/btai-20240930x10q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/talabostat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Talabostat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/talabostat

```bibtex
@misc{secapidev_pdufa_talabostat_20261116,
  title        = {Talabostat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/talabostat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_talabostat_20261116","title":"Talabostat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/talabostat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
